Company
Autobahn
Autobahn aims to improve life health for people affected by CNS disorders by driving the regenerative power of the human body.
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Autobahn is a San Diego-based, clinical-stage biotechnology company that is developing an adjunctive therapy for depressive illnesses. Autobahn’s lead molecule, ABX-002, is a potent and selective, CNS-directed thyroid hormone receptor beta (TRβ) agonist. The company is completing Phase 2 studies on therapies for people with major depressive disorder (MDD) and bipolar depression. Monograph participated in the Series C financing led by Newpath Partners in July 2024.
Loading relationship preview